Dyslipidemia is an increase or decrease in lipid levels from defined normal parameters and a major modifiable risk factor for cardiovascular disease, one of the world’s leading causes of morbidity and mortality. With a number of key brands used to treat Dyslipidemia facing patent expiration, statin and ezetimibe markets continue to face increasing genericization and the uptake of expensive add-on therapies is expected to spur growth of the Dyslipidemia market. Informa Pharma Intelligence forecasts total antidyslipidemic sales revenues to increase in the US, Japan, and five major EU markets. Datamonitor Healthcare forecasts sales from the US dyslipidemia market as remaining the most lucrative, rising to $22.3bn in 2025. Using the real-time development, pipeline event and impact tracking, and in-depth disease and market landscape reports from Informa Pharma Intelligence products Datamonitor Healthcare and Biomedtracker, this webinar will look at the market dynamics, opportunities, threats from substitutes and payer pressures for marketed drugs, and the likelihood of approval for late-phase pipeline drugs for the Dyslipidemia market. Other points to include in webinar summary:
Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.
Request live demo now:
Our team is always happy to hear from you. Please call us at:
Have an immediate and specific information need?
Browse and buy from 1000s of analysis and research reports now: